Tunnel Widening in Augmented ACL Integration Via PrP Enriched Collected Autologous Bone vs Standard ACL Technique
Launched by SCHULTHESS KLINIK · Jul 11, 2023
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical methods for fixing a torn anterior cruciate ligament (ACL), which is a common knee injury. The main goal is to see if using a special mixture of bone and platelet-rich plasma (a part of your blood that helps healing) in the knee during surgery leads to less widening of the tibial tunnel compared to the standard method that doesn’t use this mixture. Participants will be randomly assigned to one of the two groups, and they won’t know which group they are in. After 12 and 24 months, they will undergo medical exams and tests to check how well their knee is functioning.
To be eligible for the trial, participants need to be between 18 and 50 years old and have a primary ACL tear that occurred within the last 4 weeks to 6 months. They should not have other significant knee injuries or conditions, like osteoarthritis. Throughout the study, participants will be asked to report on their knee health and function at different times, including before surgery and at 6, 12, and 24 months after. This trial is currently recruiting participants, and it’s important for anyone considering joining to understand that they will be closely monitored and will contribute valuable information to help improve ACL repair techniques in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-50 years
- • Primary ACL rupture
- • Time from injury to surgery: 4 weeks to 6 months
- • Single ACL rupture (isolated rupture)
- • ACL surgery with one of the participating senior surgeons
- • Informed Consent as documented by signature
- Exclusion Criteria:
- • Concomitant ligamentous instability/rupture
- • Requirement for Meniscus suture (partial resection accepted, hoop and roots remain intact)
- • Requirement for cartilage invasive treatment (debridement accepted)
- • Osteoarthritis at index knee joint
- • Leg axis deviation over 3° valgus or 4° varus
- • Claustrophobia (contra-indication for the MRI)
- • Women who are pregnant or breast feeding or intention to become pregnant during the study
- • Known or suspected non-compliance, drug or alcohol abuse
- • Inability of the patient to follow the study procedures, e.g. language problems, psychological disorders, dementia, etc.
About Schulthess Klinik
Schulthess Klinik is a renowned medical institution based in Zurich, Switzerland, specializing in orthopedic surgery and rehabilitation. With a commitment to advancing patient care through innovative research and clinical trials, the clinic is dedicated to enhancing treatment outcomes and improving quality of life for individuals with musculoskeletal conditions. Schulthess Klinik combines state-of-the-art technology with a multidisciplinary approach, fostering collaborations among healthcare professionals to ensure comprehensive care and support for patients. Its reputation for excellence in clinical research positions Schulthess Klinik as a leader in the field, contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, , Switzerland
Patients applied
Trial Officials
Gian Salzmann, Prof.
Principal Investigator
Schulthess Klinik
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported